OHE OHE
Close
OHE
Newsletter SignupSubscribe

Antimicrobial Resistance (AMR)

The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.

Featured

Filter results by

Theme
Select the product option you would like to filter Theme
Tag
Select the product option you would like to filter Tag
Date 1
Select the product option you would like to filter Date
Date From
Date To
Author
Select the product option you would like to filter Author
Content type
Select the product option you would like to filter Content type
NetflixAntibiotics
  • Past Event
  • Ohe webinar
  • September 2022

Can we “Netflix” the Broken Antibiotics Market?

Read more
  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
  • News
  • December 2019

OHE Presents at Global AMR R&D Hub Board of Members Meeting in Paris

Read more
  • News
  • October 2019

Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance

Read more
  • News
  • September 2019

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more
  • News
  • October 2017

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017

Read more
  • News
  • September 2017

An Insurance Framework for Funding New Antibiotics

Read more
  • News
  • May 2017

Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions

Read more
  • News
  • May 2017

Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance

Read more
Load More